60. Santos C, Olmedo RE, Kim J. Sedative-hypnotic drug withdrawal syndrome: recognition and treatment [digest]. Emerg Med Pract. 2017;19(3 Suppl Points & Pearls):S1-s2. 61. Fluyau D, Revadigar N, Manobianco BE. Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther Adv Psychopharmacol. 2018;8(5):147-168. 62. Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. British journal of clinical pharmacology. 2007;64(2):198-209. 63. Barbiturate Abuse. WebMD. https://www. webmd.com/mental-health/addiction/ barbiturate-abuse Accessed July 22, 2021. 64. López-Muñoz F, Ucha-Udabe R, Alamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat. 2005;1(4):329-343. Drug Enforcement Administration. Drug Fact Sheet: Hallucinogenics. https://www. getsmartaboutdrugs.gov/publication/drug- fact-sheets Published April 2020. Accessed July 1, 2021. 66. Department of Justice, Drug Enforcement Administration. Drug Fact Sheet: Ketamine. https://www.getsmartaboutdrugs.gov/ publication/drug-fact-sheets Published April 2020. Accessed July 1, 2021. 67. Kariisa M, Scholl L, Wilson N, Seth P, Hoots B. 65. Department of Justice, Drug Overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential - United States, 2003-2017. MMWR Morbidity and mortality weekly report. 2019;68(17):388- 395. 68. Department of Justice, Drug Enforcement Administration. Drug Fact Sheet: Stimulants. https:// www.dea.gov/docu ments/2020/2020-06/2020-06-05/ stimulants-drug-fact-sheet. Published April 2020. Accessed July 22, 2021. 69. What are the signs someone is addicted to muscle relaxers? https://www. cornerstoneofrecovery.com/what-are-the- signs-someone-is-addicted-to-muscle- relaxers/ - _ftn13 Published March 5, 2020. Accessed June 17, 2021. 70. American Society of Addiction Medicine. Definition of Addiction: Adopted by the ASAM Board of Directors September 15, 2019. https://www.asam.org/Quality-Science/ definition-of-addiction Accessed June 28, 2021. 71. American Psychiatric Association. Opioid Use Disorder Diagnostic Criteria. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5. 2013. 72. Saunders JB. Substance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11. Curr Opin Psychiatry. 2017;30(4):227- 237.
73. Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019;197:78-82. 74. Speed TJ, Parekh V, Coe W, Antoine D. Comorbid chronic pain and opioid use disorder: literature review and potential treatment innovations. Int Rev Psychiatry. 2018;30(5):136-146. 75. Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741-1748. 76. Biernikiewicz M, Taieb V, Toumi M. Characteristics of doctor-shoppers: a systematic literature review. J Mark Access Health Policy. 2019;7(1):1595953. 77. Kruse CS, Kindred B, Brar S, Gutierrez G, Cormier K. Health Information Technology and Doctor Shopping: A Systematic Review. Healthcare (Basel, Switzerland). 2020;8(3):306. 78. Norton M. Best Practices for Prescribing Controlled Substances [CME]. https://www. piedmont.org/media/file/CME-Controlled- Substances-Abuse-and-Misuse.pdf. Accessed July 12, 2021. 79. U.S. Department of Health and Human Services. HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long- Term Opioid Analgesics. September 2019. 80. U.S. Food and Drug Administration. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering: FDA drug safety communication. https://www. fda.gov/drugs/drug-safety-and-availability/ fda-identifies-harm-reported-sudden- discontinuation-opioid-pain-medicines-and- requires-label-changes Published April 9, 2019. Accessed August 17, 2021. 81. Rubio G, Bobes J, Cervera G, et al. Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long- term benzodiazepine use. Eur Addict Res. 2011;17(5):262-270. 82. Pages KP, Ries RK. Use of anticonvulsants in benzodiazepine withdrawal. Am J Addict. 1998;7(3):198-204. 83. Ries RK, Roy-Byrne PP, Ward NG, Neppe V, Cullison S. Carbamazepine treatment for benzodiazepine withdrawal. Am J Psychiatry. 1989;146(4):536-537. 84. Bramness JG, Sandvik P, Engeland A, Skurtveit S. Does Pregabalin (Lyrica((R)) ) help patients reduce their use of benzodiazepines? A comparison with gabapentin using the Norwegian Prescription Database. Basic Clin Pharmacol Toxicol. 2010;107(5):883-886. 85. U.S. Food and Drug Administration. Neonatal opioid withdrawal syndrome and medication- assisted treatment with methadone and buprenorphine. https://www.fda.gov/Drugs/ DrugSafety/ucm503630.htm. Published May 26, 2016. Accessed 4-10-18.
86. Substance Abuse and Mental Health Services Administration. Medication-Assisted Treatment (MAT): Statutes, Regulations, and Guidelines. https://www.samhsa.gov/medication-assisted- treatment/statutes-regulations-guidelines. Updated June 24, 2021. Accessed July 22, 2021. 87. Florence CS, Zhou C, Luo F, Xu L. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. Med Care. 2016;54(10):901-906. 88. Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/. Accessed. 89. Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription opioid analgesics commonly unused after surgery: a systematic review. JAMA Surg. 2017;152(11):1066- 1071. 90. Berge KH, Dillon KR, Sikkink KM, Taylor TK, Lanier WL. Diversion of drugs within health care facilities, a multiple-victim crime: patterns of diversion, scope, consequences, detection, and prevention. Mayo Clin Proc. 2012;87(7):674-682. 91. Abramowitz LH, Bittinger AM. T. Diversion of Controlled Substance in Health Care Setting. Paper presented at: Physicians and Hospitals Law InstituteFebruary 5-7, 2014; Jacksonville, Florida.
18
Powered by FlippingBook